PL3256594T3 - Ulepszone dostarczanie cząstek wirusa do prążkowia i kory - Google Patents

Ulepszone dostarczanie cząstek wirusa do prążkowia i kory

Info

Publication number: PL3256594T3
Authority: PL; Poland
Prior art keywords: strain; circle; virus particles; improved delivery; delivery
Prior art date: 2015-02-10

Application number

PL16714066T

Other languages

English (en)

Inventor

Lisa M. Stanek

Lamya Shihabuddin

Original Assignee

Genzyme Corporation

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2015-02-10

Filing date

2016-02-09

Publication date

2022-02-14

2016-02-09 Application filed by Genzyme Corporation filed Critical Genzyme Corporation

2022-02-14 Publication of PL3256594T3 publication Critical patent/PL3256594T3/pl

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0085—Brain, e.g. brain implants; Spinal cord
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14151—Methods of production or purification of viral material
- C12N2750/14152—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Biomedical Technology (AREA)
General Health & Medical Sciences (AREA)
Genetics & Genomics (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biotechnology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Wood Science & Technology (AREA)
Zoology (AREA)
Molecular Biology (AREA)
General Engineering & Computer Science (AREA)
Epidemiology (AREA)
Biochemistry (AREA)
Microbiology (AREA)
Virology (AREA)
Psychology (AREA)
Biophysics (AREA)
Plant Pathology (AREA)
Physics & Mathematics (AREA)
Hospice & Palliative Care (AREA)
Psychiatry (AREA)
Orthopedic Medicine & Surgery (AREA)
Immunology (AREA)
Pain & Pain Management (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

PL16714066T 2015-02-10 2016-02-09 Ulepszone dostarczanie cząstek wirusa do prążkowia i kory PL3256594T3 (pl)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US201562114544P	2015-02-10	2015-02-10
US201562220997P	2015-09-19	2015-09-19
EP16714066.4A EP3256594B1 (en)	2015-02-10	2016-02-09	Enhanced delivery of viral particles to the striatum and cortex
PCT/US2016/017210 WO2016130591A2 (en)	2015-02-10	2016-02-09	Enhanced delivery of viral particles to the striatum and cortex

Publications (1)

Publication Number	Publication Date
PL3256594T3 true PL3256594T3 (pl)	2022-02-14

Family

ID=56614902

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL16714066T PL3256594T3 (pl)	2015-02-10	2016-02-09	Ulepszone dostarczanie cząstek wirusa do prążkowia i kory

Country Status (27)

Country	Link
US (2)	US20190111157A1 (pl)
EP (3)	EP4023758A1 (pl)
JP (4)	JP6928558B2 (pl)
KR (2)	KR102863734B1 (pl)
CN (2)	CN107530447A (pl)
AU (3)	AU2016219398A1 (pl)
BR (1)	BR112017017037A2 (pl)
CA (1)	CA2976082A1 (pl)
CL (1)	CL2017002028A1 (pl)
CR (1)	CR20170407A (pl)
DK (1)	DK3256594T3 (pl)
EA (1)	EA201791803A1 (pl)
ES (1)	ES2904504T3 (pl)
HU (1)	HUE057272T2 (pl)
IL (4)	IL296466B2 (pl)
LT (1)	LT3256594T (pl)
MX (2)	MX388264B (pl)
NZ (1)	NZ772772A (pl)
PH (1)	PH12017501436A1 (pl)
PL (1)	PL3256594T3 (pl)
PT (1)	PT3256594T (pl)
RS (1)	RS62811B1 (pl)
SG (3)	SG10201907399RA (pl)
SI (1)	SI3256594T1 (pl)
TN (1)	TN2017000353A1 (pl)
TW (1)	TWI730952B (pl)
WO (1)	WO2016130591A2 (pl)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2015191508A1 (en)	2014-06-09	2015-12-17	Voyager Therapeutics, Inc.	Chimeric capsids
CN107106689A (zh)	2014-11-05	2017-08-29	沃雅戈治疗公司	用于治疗帕金森病的aadc多核苷酸
MX2017006216A (es)	2014-11-14	2018-08-29	Voyager Therapeutics Inc	Composiciones y métodos para tratar la esclerosis lateral amiotrófica (ela).
KR102584655B1 (ko)	2014-11-14	2023-10-06	보이저 테라퓨틱스, 인크.	조절성 폴리뉴클레오티드
US11697825B2 (en)	2014-12-12	2023-07-11	Voyager Therapeutics, Inc.	Compositions and methods for the production of scAAV
AU2016219398A1 (en) *	2015-02-10	2017-09-28	Genzyme Corporation	Enhanced delivery of viral particles to the striatum and cortex
TWI707951B (zh)	2015-04-08	2020-10-21	美商健臻公司	過大腺相關載體之製造
US11020443B2 (en)	2015-04-23	2021-06-01	University Of Massachusetts	Modulation of AAV vector transgene expression
GB201508025D0 (en)	2015-05-11	2015-06-24	Ucl Business Plc	Fabry disease gene therapy
MA42934A (fr)	2015-09-24	2018-08-01	Biomarin Pharm Inc	Vecteurs de facteur viii à virus adéno-associé, particules virales associées et formulations thérapeutiques comprenant ceux-ci
WO2017189964A2 (en)	2016-04-29	2017-11-02	Voyager Therapeutics, Inc.	Compositions for the treatment of disease
US11326182B2 (en)	2016-04-29	2022-05-10	Voyager Therapeutics, Inc.	Compositions for the treatment of disease
RU2758488C2 (ru)	2016-05-18	2021-10-28	Вояджер Терапьютикс, Инк.	Модулирующие полинуклеотиды
AU2017268382B2 (en)	2016-05-18	2023-09-28	Voyager Therapeutics, Inc.	Compositions and methods of treating Huntington's disease
JP2019531787A (ja)	2016-08-30	2019-11-07	ザリージェンツオブザユニバーシティオブカリフォルニア	生物医学的ターゲティング及びデリバリーの方法並びにそれを実行するための装置及びシステム
PT3519569T (pt)	2016-09-30	2021-03-04	UNIV AUTòNOMA DE BARCELONA	Vetores de vírus adenoassociados para o tratamento de mucopolissacaridoses
CN110770344B (zh) *	2017-03-31	2024-09-17	北京三诺佳邑生物技术有限责任公司	shRNA表达框、携带其的多核苷酸序列及其应用
US10898585B2 (en)	2017-04-14	2021-01-26	Ptc Therapeutics .Inc.	Gene therapy for AADC deficiency
AU2018261790B2 (en)	2017-05-05	2024-10-03	Voyager Therapeutics, Inc.	Compositions and methods of treating amyotrophic lateral sclerosis (ALS)
WO2018204803A1 (en) *	2017-05-05	2018-11-08	Voyager Therapeutics, Inc.	Compositions and methods of treating huntington's disease
JOP20190269A1 (ar)	2017-06-15	2019-11-20	Voyager Therapeutics Inc	بولي نوكليوتيدات aadc لعلاج مرض باركنسون
CN111132626B (zh)	2017-07-17	2024-01-30	沃雅戈治疗公司	轨迹阵列引导系统
EP3662060A2 (en)	2017-08-03	2020-06-10	Voyager Therapeutics, Inc.	Compositions and methods for delivery of aav
EP3687582A4 (en)	2017-09-29	2021-07-14	Voyager Therapeutics, Inc.	RESCUE OF CENTRAL AND PERIPHERAL NEUROLOGICAL PHENOTYPE OF FRIEDREICH ATAXIA BY INTRAVENOUS ADMINISTRATION
US11434502B2 (en)	2017-10-16	2022-09-06	Voyager Therapeutics, Inc.	Treatment of amyotrophic lateral sclerosis (ALS)
EP4454654A3 (en)	2017-10-16	2025-02-19	Voyager Therapeutics, Inc.	Treatment of amyotrophic lateral sclerosis (als)
CA3096102A1 (en)	2018-04-13	2019-10-17	University Of Massachusetts	Bicistronic aav vectors encoding hexosaminidase alpha and beta-subunits and uses thereof
MX2020012077A (es)	2018-05-15	2021-03-09	Voyager Therapeutics Inc	Composiciones y metodos para el tratamiento de la enfermedad de parkinson.
CN113476484A (zh) *	2018-06-29	2021-10-08	武汉纽福斯生物科技有限公司	治疗遗传性视神经病变的组合物和方法
SG11202103151RA (en)	2018-09-28	2021-04-29	Voyager Therapeutics Inc	Frataxin expression constructs having engineered promoters and methods of use thereof
KR20210087462A (ko)	2018-10-05	2021-07-12	유니버시티 오브 매사추세츠	Gm1 및 gm2 강글리오시드증의 치료를 위한 raav 벡터
BR112021009370A2 (pt) *	2018-11-14	2021-08-17	Regenxbio Inc.	método de tratamento da doença de batten cln2, composição farmacêutica e kit
EP3927381A1 (en) *	2019-02-22	2021-12-29	The Trustees of The University of Pennsylvania	Recombinant adeno-associated virus for treatment of grn-associated adult-onset neurodegeneration
US20220307024A1 (en) *	2019-06-17	2022-09-29	Alnylam Pharmaceuticals, Inc.	Delivery of oligonucleotides to the striatum
WO2021007382A1 (en) *	2019-07-09	2021-01-14	Voyager Therapeutics, Inc.	Compositions and methods for the treatment of parkinson's disease
WO2021016505A1 (en) *	2019-07-24	2021-01-28	Voyager Therapeutics, Inc.	Compositions and methods for treating huntington's disease
JP7743075B2 (ja) *	2020-03-02	2025-09-24	国立大学法人群馬大学	ミクログリア選択的遺伝子発現ベクター
US20230133201A1 (en) *	2020-03-11	2023-05-04	Remotor Therapeutics, Inc.	Methods and materials for disseminating a protein throughout the central nervous system
US20230218526A1 (en) *	2020-06-30	2023-07-13	Seqirus UK Limited	Cold filtration of oil-in-water emulsion adjuvants
JP2024505885A (ja) *	2021-01-27	2024-02-08	リサーチインスティチュートアットネイションワイドチルドレンズホスピタル	リソソーム酸リパーゼ欠損症（ｌａｌ－ｄ）の治療のための材料及び方法
WO2023113806A1 (en)	2021-12-16	2023-06-22	Affinia Therapeutics, Inc.	Recombinant aav for treatment of neural disease
EP4323531A1 (en)	2021-04-12	2024-02-21	Affinia Therapeutics Inc.	Recombinant aav for treatment of neural disease
US20250333758A1 (en) *	2021-12-15	2025-10-30	Genans Biotechnology Co., Ltd	Microglia having car and use thereof
US20250297279A1 (en) *	2021-12-15	2025-09-25	Genans Biotechnology Co., Ltd	Recombinant aav vectors and use thereof
AU2023364350A1 (en)	2022-10-19	2025-06-05	Affinia Therapeutics Inc.	Recombinant aavs with improved tropism and specificity
WO2025151454A1 (en) *	2024-01-08	2025-07-17	AskBio Inc.	Method or system of infusing and/or predicting an infusate volume
WO2025227063A1 (en)	2024-04-26	2025-10-30	Affinia Therapeutics Inc.	Recombinant aavs with improved tropism and specificity

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4692147A (en)	1980-04-02	1987-09-08	Medtronic, Inc.	Drug administration device
US5735815A (en)	1993-07-26	1998-04-07	Sentinel Medical, Inc.	Method of using fluid jet surgical cutting tool
EP0931158A1 (en)	1996-09-06	1999-07-28	The Trustees Of The University Of Pennsylvania	An inducible method for production of recombinant adeno-associated viruses utilizing t7 polymerase
US6042579A (en)	1997-04-30	2000-03-28	Medtronic, Inc.	Techniques for treating neurodegenerative disorders by infusion of nerve growth factors into the brain
US6989264B2 (en)	1997-09-05	2006-01-24	Targeted Genetics Corporation	Methods for generating high titer helper-free preparations of released recombinant AAV vectors
US6566118B1 (en)	1997-09-05	2003-05-20	Targeted Genetics Corporation	Methods for generating high titer helper-free preparations of released recombinant AAV vectors
ES2326893T3 (es) *	1998-05-27	2009-10-21	Genzyme Corporation	Vectores aav para la fabricacion de medicamentos para administracion potenciada por conveccion.
DE60039766D1 (de)	1999-08-09	2008-09-18	Targeted Genetics Corp	Terologen nukleotidsequenz von einem rekombinanten viralen vektor durch ausgestaltung der sequenz in einer art und weise, dass basenpaarungen innerhalb der sequenz entstehen
ES2256265T3 (es)	2000-06-01	2006-07-16	University Of North Carolina At Chapel Hill	Vectores de parvovirus duplicados.
EP1402043A1 (en)	2001-07-03	2004-03-31	Institut National De La Sante Et De La Recherche Medicale (Inserm)	Methods of administering vectors to synaptically connected neurons
US6723551B2 (en)	2001-11-09	2004-04-20	The United States Of America As Represented By The Department Of Health And Human Services	Production of adeno-associated virus in insect cells
CA2915124C (en)	2001-11-13	2018-08-14	The Trustees Of The University Of Pennsylvania	A method of detecting and/or identifying adeno-associated virus (aav) sequences and isolating novel sequences identified thereby
GB2389791B (en)	2002-04-30	2006-12-13	Steven Gill	Implantable drug delivery pump
PT1625210E (pt)	2003-05-21	2011-03-15	Genzyme Corp	Métodos para produzir preparações de vírions de aav recombinantes substancialmente livres de capsídeos vazios
CA2581714C (en)	2004-10-05	2017-09-12	Avigen, Inc.	Stepped cannula
US8283151B2 (en)	2005-04-29	2012-10-09	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Isolation, cloning and characterization of new adeno-associated virus (AAV) serotypes
CN107007842A (zh) *	2005-05-02	2017-08-04	建新公司	神经代谢疾病的基因治疗
WO2007024841A2 (en) *	2005-08-23	2007-03-01	The Regents Of The University Of California	Reflux resistant cannula and system for chronic delivery of therapeutic agents using convection-enhanced delivery
EP2007795B1 (en)	2006-03-30	2016-11-16	The Board Of Trustees Of The Leland Stanford Junior University	Aav capsid proteins
SI2019683T2 (sl)	2006-04-25	2022-10-28	The Regents Of The University Of California	Dajanje rastnih faktorjev za zdravljenje motenj CŽS
EP2023949A4 (en)	2006-04-26	2009-08-26	Univ California	COMPOSITIONS AND METHODS FOR CONVECTION-REINFORCED RELEASE OF NEUROTHERAPEUTICS WITH HIGH MOLECULAR WEIGHT
WO2008144585A1 (en)	2007-05-17	2008-11-27	Medgenesis Therapeutix Inc.	Convection-enhanced delivery catheter with removable stiffening member and method for using same
BRPI1007155A2 (pt)	2009-01-29	2017-05-30	Univ Of California San Francisco	métodos para tratar um distúrbio neurológico cortical, e para dispensar um agente terapêutico para o córtex em um primata
CN102803478B (zh)	2009-06-16	2016-04-27	建新公司	用于纯化重组aav载体的改进方法
US8663624B2 (en)	2010-10-06	2014-03-04	The Regents Of The University Of California	Adeno-associated virus virions with variant capsid and methods of use thereof
CA2827380C (en) *	2011-02-12	2020-08-25	University Of Iowa Research Foundation	Therapeutic nucleic acids
JP6224459B2 (ja)	2011-02-17	2017-11-01	ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア	組織特異性を改変し、ａａｖ９媒介遺伝子導入を改善するための組成物および方法
EP4600255A3 (en) *	2014-05-02	2025-10-22	Genzyme Corporation	Aav vectors for retinal and cns gene therapy
AU2016219398A1 (en) *	2015-02-10	2017-09-28	Genzyme Corporation	Enhanced delivery of viral particles to the striatum and cortex
CN111417231A (zh)	2019-01-04	2020-07-14	青岛海尔股份有限公司	电磁波发生系统及具有该电磁波发生系统的加热装置

2016
- 2016-02-09 AU AU2016219398A patent/AU2016219398A1/en not_active Abandoned
- 2016-02-09 CN CN201680020700.4A patent/CN107530447A/zh active Pending
- 2016-02-09 US US15/549,962 patent/US20190111157A1/en not_active Abandoned
- 2016-02-09 KR KR1020247000976A patent/KR102863734B1/ko active Active
- 2016-02-09 EA EA201791803A patent/EA201791803A1/ru unknown
- 2016-02-09 SI SI201631446T patent/SI3256594T1/sl unknown
- 2016-02-09 IL IL296466A patent/IL296466B2/en unknown
- 2016-02-09 EP EP21198081.8A patent/EP4023758A1/en not_active Withdrawn
- 2016-02-09 WO PCT/US2016/017210 patent/WO2016130591A2/en not_active Ceased
- 2016-02-09 ES ES16714066T patent/ES2904504T3/es active Active
- 2016-02-09 CA CA2976082A patent/CA2976082A1/en active Pending
- 2016-02-09 IL IL313840A patent/IL313840A/en unknown
- 2016-02-09 JP JP2017560479A patent/JP6928558B2/ja active Active
- 2016-02-09 PT PT167140664T patent/PT3256594T/pt unknown
- 2016-02-09 LT LTEPPCT/US2016/017210T patent/LT3256594T/lt unknown
- 2016-02-09 MX MX2017010370A patent/MX388264B/es unknown
- 2016-02-09 CR CR20170407A patent/CR20170407A/es unknown
- 2016-02-09 HU HUE16714066A patent/HUE057272T2/hu unknown
- 2016-02-09 KR KR1020177025285A patent/KR102625784B1/ko active Active
- 2016-02-09 BR BR112017017037A patent/BR112017017037A2/pt not_active Application Discontinuation
- 2016-02-09 SG SG10201907399RA patent/SG10201907399RA/en unknown
- 2016-02-09 DK DK16714066.4T patent/DK3256594T3/da active
- 2016-02-09 PL PL16714066T patent/PL3256594T3/pl unknown
- 2016-02-09 CN CN202210805297.3A patent/CN116019934A/zh active Pending
- 2016-02-09 NZ NZ772772A patent/NZ772772A/en unknown
- 2016-02-09 TN TNP/2017/000353A patent/TN2017000353A1/en unknown
- 2016-02-09 RS RS20220044A patent/RS62811B1/sr unknown
- 2016-02-09 SG SG11201706445SA patent/SG11201706445SA/en unknown
- 2016-02-09 EP EP23150591.8A patent/EP4219728A3/en active Pending
- 2016-02-09 EP EP16714066.4A patent/EP3256594B1/en active Active
- 2016-02-10 SG SG10201912926VA patent/SG10201912926VA/en unknown
- 2016-02-15 TW TW105104342A patent/TWI730952B/zh active
2017
- 2017-08-08 CL CL2017002028A patent/CL2017002028A1/es unknown
- 2017-08-08 IL IL253894A patent/IL253894B/en unknown
- 2017-08-10 PH PH12017501436A patent/PH12017501436A1/en unknown
- 2017-08-10 MX MX2021004294A patent/MX2021004294A/es unknown
2021
- 2021-07-22 IL IL285060A patent/IL285060B2/en unknown
- 2021-08-06 JP JP2021129519A patent/JP2021178861A/ja active Pending
2022
- 2022-06-28 AU AU2022204583A patent/AU2022204583A1/en not_active Abandoned
- 2022-07-29 US US17/816,139 patent/US12465657B2/en active Active
2023
- 2023-02-10 JP JP2023018846A patent/JP2023058630A/ja active Pending
2024
- 2024-12-25 JP JP2024228114A patent/JP2025060823A/ja active Pending
2025
- 2025-02-26 AU AU2025201381A patent/AU2025201381A1/en active Pending

Also Published As

Publication number	Publication date
IL313840A (en)	2024-08-01
IL285060B (en)	2022-10-01
SG11201706445SA (en)	2017-09-28
JP6928558B2 (ja)	2021-09-01
TWI730952B (zh)	2021-06-21
SI3256594T1 (sl)	2022-07-29
LT3256594T (lt)	2022-02-10
RS62811B1 (sr)	2022-02-28
MX388264B (es)	2025-03-19
HUE057272T2 (hu)	2022-04-28
PH12017501436A1 (en)	2018-01-15
JP2023058630A (ja)	2023-04-25
KR102863734B1 (ko)	2025-09-25
IL253894A0 (en)	2017-10-31
MX2017010370A (es)	2017-12-14
AU2016219398A1 (en)	2017-09-28
WO2016130591A2 (en)	2016-08-18
EP4219728A3 (en)	2023-08-23
JP2021178861A (ja)	2021-11-18
EP4219728A2 (en)	2023-08-02
TN2017000353A1 (en)	2019-01-16
ES2904504T3 (es)	2022-04-05
WO2016130591A3 (en)	2016-11-10
KR102625784B1 (ko)	2024-01-15
EA201791803A1 (ru)	2017-11-30
US12465657B2 (en)	2025-11-11
NZ772772A (en)	2024-12-20
PT3256594T (pt)	2022-01-18
CN116019934A (zh)	2023-04-28
CL2017002028A1 (es)	2018-04-13
IL296466A (en)	2022-11-01
CA2976082A1 (en)	2016-08-18
JP2018506585A (ja)	2018-03-08
KR20170110718A (ko)	2017-10-11
JP2025060823A (ja)	2025-04-10
IL285060A (en)	2021-08-31
IL296466B2 (en)	2024-11-01
EP4023758A1 (en)	2022-07-06
CR20170407A (es)	2017-11-14
IL253894B (en)	2021-08-31
HK1246340A1 (zh)	2018-09-07
IL285060B2 (en)	2023-02-01
NZ735290A (en)	2023-10-27
US20190111157A1 (en)	2019-04-18
SG10201912926VA (en)	2020-02-27
US20220395586A1 (en)	2022-12-15
SG10201907399RA (en)	2019-09-27
EP3256594B1 (en)	2021-10-20
BR112017017037A2 (pt)	2018-04-10
CN107530447A (zh)	2018-01-02
IL296466B1 (en)	2024-07-01
TW201642909A (zh)	2016-12-16
AU2025201381A1 (en)	2025-03-20
DK3256594T3 (da)	2022-01-24
MX2021004294A (es)	2021-06-04
KR20240010539A (ko)	2024-01-23
AU2022204583A1 (en)	2022-07-21
EP3256594A2 (en)	2017-12-20

Publication	Publication Date	Title
PL3256594T3 (pl)	2022-02-14	Ulepszone dostarczanie cząstek wirusa do prążkowia i kory
IL280905A (en)	2021-04-29	Methods of modulating drug plasma levels using erythrohydroxybupropion
ZA201703163B (en)	2019-03-27	Rna guided eradication of human jc virus and other polyomaviruses
SG11201606624WA (en)	2016-09-29	Antibody moleules to dengue virus and uses thereof
MA40595A (fr)	2021-05-26	Récepteurs chimériques et utilisations de ceux-ci en thérapie immunitaire
IL249061A0 (en)	2017-01-31	Combination, composition, and method of administering the combination or composition to animals
IL286265A (en)	2021-10-31	A new tilapia virus and its uses
IL247870A0 (en)	2016-11-30	The hemagglutinin antibodies against influenza b virus and methods of use
IL252026B (en)	2021-10-31	Humanized anti-complement factor c1q antibodies and uses thereof
ZA201700165B (en)	2019-06-26	Influenza virus vaccines and uses thereof
PT3274370T (pt)	2020-01-30	Anticorpos anti-ceacam6 e utilizações dos mesmos
PT3119431T (pt)	2024-04-16	Anticorpos antagonistas dirigidos contra o peptídeo relacionado com o gene da calcitonina e métodos de utilização dos mesmos
PL3198009T3 (pl)	2022-01-24	Onkolityczne wirusy nowotworowe i sposoby zastosowania
IL252418B (en)	2021-01-31	Envenomation therapies and related pharmaceutical compositions, systems and kits
SG11201610443WA (en)	2017-01-27	Influenza virus vaccines and uses thereof
DK3212204T3 (da)	2019-08-12	Mikroniserede æggeskalsmembranpartikler og anvendelsen deraf til at fremme helingen af sår
IL259202A (en)	2018-07-31	Modified immune cells and uses thereof
PL3154515T3 (pl)	2021-08-09	Udoskonalenia kompozycji donosowych i sposób ich stosowania
IL258856A (en)	2018-06-28	Solabegron zwitterion and uses thereof
IL249582B (en)	2021-04-29	Use of materials incorporating microparticles for avoiding the proliferation of contaminants
HUE055330T2 (hu)	2021-11-29	Javított aktivitású exoglükanázok variánsai és alkalmazásaik
SG11201704942QA (en)	2017-07-28	Dengue virus vaccine compositions and methods of use thereof
PL3215181T3 (pl)	2025-05-19	Sposoby wytwarzania kompozycji o ulepszonym profilu bezpieczeństwa zawierających pankreatynę i kompozycje odpowiednie do zastosowania farmaceutycznego
PL3158076T3 (pl)	2022-05-30	Warianty egzoglukanaz o polepszonej aktywności i ich zastosowania
ITUB20152292A1 (it)	2017-01-21	Accorgimenti per incastonare pietre e solitari.